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between the years of 1998-2006. This cohort included patients with two 
or more risk factors for lung cancer, including history of smoking (> 20 
pack years), asbestos exposure, chronic obstructive pulmonary disease 
(COPD), and prior history of aerodigestive cancer. No pre-screening 
with sputum cytology was performed. Follow-up AFB procedures were 
performed on 116 subjects, an average of 11 months after the ﬁrst AFB.
Results: Patients were on average 63 years old, male (66%), and Cau-
casian (94%), 65% with COPD, and never, former, and current smokers 
represented 7%, 63% and 30% respectively. Three biopsies, on average, 
were taken during each bronchoscopy. On the baseline AFB, 53% of 
patients had metaplasia or a higher grade diagnosis; 11% with a dyspla-
sia and 6% with carcinoma in-situ (CIS). Among current smokers, 77% 
had premalignant lesions compared to 45% of the former smokers. In 
regression models, male gender, COPD and current or former smoking 
status were signiﬁcant predictors of lesion detection. On the second 
AFB, 73/116 (63%) had metaplasia or a worse diagnosis; 20% with 
dysplasia or CIS. Premalignant lesions persisted in 82% of patients, 
with 9-25% having higher grade lesions on follow-up. Premalignant 
lesions persisted in former and current smokers (55% and 84% respec-
tively) and in patients with COPD (66%). Male gender, COPD, and 
smoking remained signiﬁcant predictors of persistence and progression 
of premalignancy on follow-up AFB. Cancer was diagnosed in 4% of 
these patients at > 6 months after the ﬁrst screening procedure. 
Conclusions: Selecting patients for lung cancer screening with AFB, 
based solely on known risk factors for lung cancer, is an efﬁcient 
means for detecting premalignant lesions. The level of persistence and 
progression of these lesions on follow-up AFB is signiﬁcant for all 
grades, even metaplasia. This suggests that metaplasia is not simply 
a transient change to the epithelium, even in former smokers, and the 
detection of metaplasia over multiple AFB examinations may confer 
the risk of a damaged or progressively worsening airway. 
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Background: Positron emission tomography (PET) has been reported 
as being useful in the assessment of indeterminate pulmonary nodules 
found on thoracic computed tomography (CT) scans in both clini-
cal and screening settings. Sensitivity and speciﬁcity for malignancy 
has been reported as ranging from 69-97% and 70-91% respectively. 
Positive and negative predictive values have been 87-90% and 71-84% 
respectively. The performance of PET is known to be reduced with tu-
mours that have relatively low metabolism or are less than 8mm in size. 
Our objective was to evaluate the utility of PET scan in CT detected 
suspicious lesions found in a lung cancer screening program.
Method: As part of several NCI sponsored chemoprevention trials 
(N01-CN-85188, PO1 CA096964-01A1, U01CA96109) thoracic CT 
scan has been incorporated into an early lung cancer detection program 
since June 2000. Volunteers recruited from the community include 
current or former smokers at least 50 years of age with a 30 pack/year 
smoking history. All suspicious lesions detected on thoracic CT scan 
that were referred for surgical resection and had a preoperative PET 
scan were evaluated. Suspicious lesions were deﬁned as those found to 
be growing or showing an increase in a solid component on serial CT 
scan, or of a large size (>10mm) at the baseline screening CT scan.
Results: A total of 25 lesions have had both a preoperative PET scan 
and surgical resection. This included 18 malignant lesions (9 with se-
rial CT growth and 9 at baseline CT) and 7 benign lesions. The mean 
size of malignant lesions was 15mm (range 7-33mm) and of benign 
lesions was 13mm (range 10-17mm). The majority of malignant lesions 
were adenocarcinoma (16/18);one squamous cell and one small cell 
carcinoma were also detected. CT appearance of the malignant lesions 
included 56%(10/18) solid lesions, 22%(4/18) semisolid lesions and 
22%(4/18) nonsolid lesions. One lesion demonstrated a pure replace-
ment growth pattern consistent with bronchioloalveolar carcinoma 
(BAC). Benign lesions included inﬂammatory lesions (5/7), amyloid 
(1/7) and hamartoma (1/7). A total of 39%(7/18) of malignant lesions 
were PET positive and 43%(3/7) of benign lesions were PET positive. 
The average size of PET positive malignant lesions was 18.6mm (range 
10-33mm) and PET negative malignant lesions was 13mm (range 7-20 
mm). Based on CT appearance, 50% of solid malignant lesions were 
PET positive and 25% of semisolid/nonsolid malignant lesions were 
PET positive. The sensitivity, speciﬁcity, positive predictive value and 
negative predictive value of PET scan were 39%, 57%, 70% and 27% 
respectively.
Conclusions: The lower performance of PET in this series compared 
to previously reported studies cannot be attributed to small size of the 
lesions or preponderance of BAC. Further clinical investigations should 
be performed for lesions that are growing or show an increase in the 
solid component on thoracic CT scan despite a negative PET.
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Background: The addition of L-BLP25 as maintenance therapy 
in patients with non-progressive stage IIIB or IV NSCLC has been 
investigated in a randomized, open-label, controlled, multi-centre phase 
IIB study. A survival beneﬁt of 4.4 months was reported in the patients 
that received L-BLP25 in addition to best supportive care (BSC) [Butts 
et al., J Clin Oncol 2005; 23: 6674-6681). In addition, in March 2006, 
a further survival analysis of this trial was conducted to identify the me-
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dian survival of the subset of patients with stage IIIB locoregional (LR) 
disease. The results for this subgroup are now available and are reported 
here together with the updated survival for the overall population. 
Method: 171 patients with ECOG 0-2 stage IIIB/IV NSCLC that had 
stable or responding disease after any ﬁrst-line chemotherapy (CT) 
with or without radiotherapy were randomized 1:1 to receive either L-
BLP25 plus best supportive care (BSC) or BSC alone. Randomization 
was stratiﬁed by stage of disease (IIIB LR or stage IIIB with malignant 
pleural effusion and stage IV). Patients in the L-BLP25 arm received a 
single i.v. dose of cyclophosphamide 300mg/m2 followed by 8 weekly 
sc immunizations with L-BLP25 (1000μg). Subsequent immunizations 
were administered at 6-wk intervals. An analysis of 65 patients with 
stage IIIB LR disease was conducted, and the results are shown in the 
table below together with the updated 3 year survival for the overall 
population. 
Results: 
 Overall Population Stage IIIB subgroup
 BSC L-BLP25 + BSC Total BSC
L-BLP25 + 
BSC Total
N 83 88 171 30 35 64
Median 
follow up 
(mths)
56 51 52 57 53 53
Median 
Survival 
(mths)
13.0 17.2 p=0.085* 13.3 30.6 p=NS**
95% CI 11.2, 16.2 12.9, 24.2  9.6, 28.1 13.4, -  
Hazard 
Ratio   0.75   0.55
95% CI   0.53, 1.04   0.30, 1.00
1 yr OS 46 (55) 55 (63)  17 (57) 24 (69)  
2 yr OS 22 (27) 36 (41)  10 (33) 20 (57)  
3 yr OS 14 (17) 27 (31)  8 (27) 17 (49)  
* P-value; adjusted for multiple comparisons. Unadjusted p-values for this subgroup based on a Cox 
model including response to ﬁrst-line treatment; 0.0497
**P-value of the primary analysis (March 2004) was p=0.112 
Conclusion: A 17.3 month difference in median survival and 45% 
reduction in mortality were seen with maintenance therapy with 
L-BLP25 in patients with stage IIIB LR NSCLC. The difference in 
efﬁcacy identiﬁed in this subgroup versus patients with IIIB MPE or 
stage IV disease, could potentially be a result of lower tumor burden 
or less advanced disease. On the basis of these results, a phase III trial 
(“START”) has been initiated to investigate the addition of mainte-
nance therapy with L-BLP25 to BSC in patients with unresectable stage 
III NSCLC. 
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Background: The clusterin gene is frequently expressed in NSCLC 
and encodes a cytoprotective chaperone protein that is upregulated in 
response to apoptotic stimuli such as chemotherapy. OGX-011 is a sec-
ond-generation antisense oligonucleotide that inhibits clusterin expres-
sion, thus enhancing the apoptotic effects of chemotherapy. Previous 
phase I studies with docetaxel suggested an OGX-011 dose of 640mg 
was feasible and biologically active; therefore, the current study began 
with a run-in phase with 480mg of OGX-011.
Methods: Eligibility criteria: stage IIIB/IV NSCLC; no prior chemo-
therapy; ≥ 1 measurable lesion; ECOG ≤1; adequate organ function; no 
active CNS metastasis. Treatment: OGX-011 is given as a 2-hour infu-
sion. There is an initial loading phase with 3 doses of OGX-011 alone 
in 1 week, followed by weekly OGX-011 with standard chemotherapy: 
gemcitabine (1250 mg/m2) Days 1+8 and either cisplatin (75 mg/m2) or 
carboplatin (AUC=5) Day 1 q21 days, (maximum 6 cycles).
Results: 85 pts (phase 1=10 and phase 2=75) were enrolled between 
Dec, 2004 and Nov, 2006. As no unexpected dose limiting toxicities 
were noted in the ﬁrst 3 patients who received 480mg of OGX-011, the 
dose was escalated, as planned, to 640 mg for the remaining patients. 
Data are available on the ﬁrst 53 pts; all received ≥1 dose of OGX-011 
and were considered evaluable for safety and efﬁcacy. Demographics: 
female (47%); stage IV (87%); median age 61 (45-79) yrs; ECOG PS = 
1 (62%). The median number of cycles delivered was 4. Principal grade 
3/4 toxicities were hematologic: neutropenia (32%) + thrombocytope-
nia (17%). Other common toxicities included fatigue, nausea, vomiting, 
fever, chills, constipation, + anorexia. Two Serious Adverse Events 
previously reported as associated with gemcitabine/platinum therapy 
were documented: acute cortical blindness with stroke + thrombotic 
thrombocytopenic purpura. Responses: conﬁrmed PRs 13 (ORR = 
24%); median duration of PR: 105 days (46-336+); median PFS: 140 
days (2-422+); 79% of pts have progressed; 47% have died. Of the 
ﬁrst 34 patients who have all been followed for ≥ 1 yr, 18/34 (53%) 
survived > 1 yr; 14/18 (78%) remain alive as of March 06, 2006. Data 
will be presented for all 85 patients.
Conclusions: This combination is feasible and tolerable. The 1-yr 
survival rate ≥50% may justify a randomized phase III trial. OGX-011 
is being developed by OncoGenex Technology Inc. + Isis Pharmaceu-
ticals Inc.
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Background: Angiogenesis, the formation of new blood vessels, is 
an essential process during growth and progression of different solid 
